Interleukin-15: a new cytokine target for the treatment of inflammatory diseases

McInnes, I. B. and Gracie, J. A. (2004) Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Current Opinion in Pharmacology, 4(4), pp. 392-397. (doi:10.1016/j.coph.2004.04.003) (PMID:15251134)

Full text not currently available from Enlighten.


Interleukin (IL)-15 is a pleiotropic pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis and pulmonary inflammatory diseases. IL-15 promotes activation of T cells, neutrophils and macrophages, and is critical to dendritic cell function in several model systems. Recent emerging data suggest that IL-15 may serve as a useful therapeutic target across a range of disease states. Advances in the past year highlight the beneficial effect of IL-15 neutralisation in models of psoriasis and diabetes. Further evidence for IL-15 expression and effector function has emerged across a range of rheumatic disorders, including juvenile inflammatory arthritis, rheumatoid arthritis and Kawasaki disease. These data hold promise for therapeutic targeting in ongoing human studies and those in the near future.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Gracie, Professor Alastair
Authors: McInnes, I. B., and Gracie, J. A.
Subjects:R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Current Opinion in Pharmacology

University Staff: Request a correction | Enlighten Editors: Update this record